TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05898854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPi-46
Description: Gastric or gatro-esophageal junction cancer patients undergo 68Ga-FAPi-46 PET/CT at primary staging and at restaging
Study: NCT06330116

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IQoro
Description: Please refer to arm/group description for information

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: eXciteosa
Description: Please refer to arm/group description for information

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Grouptraining
Description: Please refer to arm/group description for information
Study: NCT05669976

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety Planning Intervention with Navigation Services
Description: A patient navigation (PN) intervention for SGM youth/emerging adults designed to target mechanisms (i.e., decreasing thwarted belongingness and increasing suicide-related coping skills) that theoretically underlie suicide. The proposed intervention integrates a single-session, empirically supported, suicide prevention intervention (Safety Planning Intervention; SPI) with PN services (PN+SPI). The patient navigator will deliver the SPI and continue frequent contact for the purpose of providing motivational enhancement, problem-solving, reinforcing coping strategies, and connecting participants to mental health and social support resources (e.g., SGM-specific support groups within the community).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Safety Planning Intervention
Description: The Safety Planning Intervention (SPI) is a single-session, empirically supported, suicide prevention intervention. The patient navigator will deliver the SPI.
Study: NCT05078086

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06133517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: Sacituzumab govitecan is administered at 10 mg/kg as an intravenous (IV) infusion on Days 1 and 8 of a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: ZIM is administered at 360 mg every 3 weeks as an intravenous (IV) infusion on Day 1 of a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domvanalimab
Description: DOM is administered at 1200 mg every 3 weeks as an intravenous (IV) infusion on Day 1 of a 21-day cycle.
Study: NCT05230758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin hydrochloride (HCl) 500mg tablet
Description: Metformin HCl 500mg tablets contain 500mg of active pharmaceutical ingredient (API) and are white, round, biconvex, film-coated tablets, with a score line on one face and debossed with HMR on the other. Each tablet contains the non-medicinal ingredients magnesium stearate and povidone. Tablet coating is comprised of hydroxypropyl methylcellulose, polyethylene glycol and titanium dioxide.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching white round tablet containing excipients only. The placebo tablets will match the active drug as closely as possible in terms of appearance.
Study: NCT04269213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV
Study: NCT05521672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adipose derived allogenic mesenchymal stem cells (adAMSC)
Description: adAMSC will be administered in the perilesional adipose tissue, through a laparoscopic procedure
Study: NCT05538910

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nicotine Patch
Description: Comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Study drug: 7.5 mg Nicotine Patch which will be administered in a double blind, randomized manner
Study: NCT06177873

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: foot bath
Description: On the morning of surgery, the purpose of the study will be explained to the patients and their written consent will be obtained. Then, Introductory Information Form, STAI and VASS were applied. The pain level of the patients will be evaluated with VAS-Pain 4 hours after the surgery. SAI and VAS-Comfort will be applied to patients with pain level 4 and above. Then, patients in the experimental group will receive a hot water foot bath for 20 minutes. Before the hot water foot bath, patients will be lifted from their beds and placed on the chair in the room. Hot water will be poured into the foot bath tub and the patient will be asked to put his feet in the water. The water level will be adjusted to include the patients ankles. The temperature of the water will be constantly checked with a water thermometer and kept at 41-42 °C. A hot water foot bath will be applied for 20 minutes and then the patients feet will be dried with a towel.
Study: NCT05777603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aerosolized aztreonam
Description: antibiotic with gram-negative bacteria coverage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aerosolized vancomycin
Description: antibiotic with gram-positive bacteria coverage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: standard of care therapy/monoclonal antibody for patients with advanced NSCLC
Study: NCT06434883

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Anxiety/Depression Program
Description: Participants will complete the Headspace Anxiety/Depression Program, which is a 21 day program based on CBT, combined with mindfulness. The program is trans-diagnostic in nature (i.e. addresses both anxiety and depression symptoms).

Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist
Description: Participants will continue their regular routines for an 21 day period and will not be assigned to an intervention.
Study: NCT06096844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05458882

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: living with food allergy educational booklet
Description: An educational booklet giving information on social and eating out habits as well as reaction rates in food allergy Irish children.
Study: NCT06062108

Intervention type: OTHER
Intervention: Pain evaluation
Description: All included patients will have an evaluation of their pain, if they have no pain, the assessment stop with one date (pain or no pain), if they have pain, an assessment is done (localization of the pain, pain intensity), if they have a pain duration over 3 months, a DN4 questionnaire, HAD scale, ISI scale and SF-1 questionnaire is evaluated.
Study: NCT05557877

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-Dose Aspirin
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo breast biopsy
Study: NCT06197776

Intervention type: DRUG
Intervention: cisplatin-based chemoradiotherapy combined with immunotherapy
Description: Chemotherapy:cisplatin-based chemotherapy~GP/TP/PF/TPF~Choice of chemotherapy regimen is decided by patient's doctor in charge.~Radiation: Intensity Modulated Radiation Therapy~All target volumes will be outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes are defined in accordance with the International Commission on Radiation Units and Measurements Reports 83. The prescribed dose is 70-72 Gy to PTVp (Planning target volume of the primary tumor), 64-70 Gy to PTVn (Planning target volume of the lymph node),60- 64Gy to PTV1 (High-risk planning target volume), and 54-58 Gy to PTV2 (Low-risk planning target volume) in 30-32 fractions. The details of dose limits for organs at risk are based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225).~Immunotherapy:PD-1 blocking antibody
Study: NCT04430309

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baduanjin exercise program
Description: The sessions includes 10-minute warm-up, 40-minute Baduanjin exercise and 10-minute cool down.
Study: NCT04949256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m\^2 Q3W via IV infusion, as part of investigator's choice TP chemotherapy.
Study: NCT06327646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple Micronutrient Supplement Blister
Description: MMS in a blister pack along with related job aids, counselling during ANC, etc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple Micronutrient Supplement Bottle
Description: MMS in bottles along with related job aids, counselling during ANC, etc.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Folic Acid Blister
Description: Standard of Care - IFA in a blister pack along with related job aids, counselling during ANC, etc.
Study: NCT04613375

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine sample collection
Description: Serotype specific UAD (urinary antigen detection) test

Intervention type: DIAGNOSTIC_TEST
Intervention: Saliva collection
Description: Streptococcus pneumonia identification in saliva samples by culture or PCR / RSV identification in saliva samples by PCR
Study: NCT04652726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran
Description: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL solution for subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile normal saline (0.9% sodium chloride in water for subcutaneous injection)
Study: NCT05138133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anifrolumab
Description: Anifrolumab intravenous infusion (IV)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravenous infusion (IV)
Study: NCT04430309

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brisk walking program
Description: The sessions includes 10-minute warm-up, 40-minute brisk walking and 10-minute cool down.
Study: NCT05018299

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: FB704A placebo
Description: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FB704A
Description: Anti-IL-6 antibody
Study: NCT06398990

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Exercise Therapy Approach
Description: It will continue twice a week for 12 weeks. After the initial evaluation of the cases, one-on-one, face-to-face training will be provided with the patient in the first week (2 sessions) in order to ensure their compliance with the treatment and to fully understand the treatment method. Then, treatments will be carried out synchronously with the patients twice a week via the online platform (Zoom).
Study: NCT05801718

Intervention type: DIAGNOSTIC_TEST
Intervention: Growth parameters & body mass index
Description: measuring the anthropometric measurements including: Weight, height/ length, head circumference, mid arm circumference\& skin fold thickness and measuring body mass index.

Intervention type: DIAGNOSTIC_TEST
Intervention: Growth parameters & body mass index
Description: measuring the anthropometric measurements including: Weight, height/ length, head circumference, mid arm circumference\& skin fold thickness and measuring body mass index.

Intervention type: DIAGNOSTIC_TEST
Intervention: Growth parameters & body mass index
Description: measuring the anthropometric measurements including: Weight, height/ length, head circumference, mid arm circumference\& skin fold thickness and measuring body mass index.

Intervention type: DIAGNOSTIC_TEST
Intervention: Growth parameters & body mass index
Description: measuring the anthropometric measurements including: Weight, height/ length, head circumference, mid arm circumference\& skin fold thickness and measuring body mass index.

Intervention type: DIAGNOSTIC_TEST
Intervention: Growth parameters & body mass index
Description: measuring the anthropometric measurements including: Weight, height/ length, head circumference, mid arm circumference\& skin fold thickness and measuring body mass index.

Intervention type: DIAGNOSTIC_TEST
Intervention: Growth parameters & body mass index
Description: measuring the anthropometric measurements including: Weight, height/ length, head circumference, mid arm circumference\& skin fold thickness and measuring body mass index.
Study: NCT05976750

Intervention type: DEVICE
Intervention: Lotrafilcon A contact lenses
Description: CE-marked silicone hydrogel contact lenses for daily wear use

Intervention type: DEVICE
Intervention: Balafilcon A contact lenses
Description: CE-marked silicone hydrogel contact lenses for daily wear use
Study: NCT03981263

Intervention type: DEVICE
Group type: OTHER
Intervention: MEAVANTI prothesis
Description: The experimental prosthesis is the MEAVANTI prosthesis (custom-made non-adherent prosthesis in silicone) which can be calibrated to 5 grams near the breast that remains after a mastectomy to create a visual symmetry but also a weight symmetry.~This prosthesis takes into account the curve of the breasts and the morphological details such as: skin color of the patients, size of the nipples, height of the nipples, shape of the breast.~The measurements of the patients will be taken using a 3D scanner (i.e. a scanner that corresponds to a 3d scanning and acquiring device (images), not irradiating), a scale and a colour chart.

Intervention type: DEVICE
Group type: OTHER
Intervention: MEAVANTI prothesis
Description: The experimental prosthesis is the MEAVANTI prosthesis (custom-made non-adherent prosthesis in silicone) which can be calibrated to 5 grams near the breast that remains after a mastectomy to create a visual symmetry but also a weight symmetry.~This prosthesis takes into account the curve of the breasts and the morphological details such as: skin color of the patients, size of the nipples, height of the nipples, shape of the breast.~The measurements of the patients will be taken using a 3D scanner (i.e. a scanner that corresponds to a 3d scanning and acquiring device (images), not irradiating), a scale and a colour chart.
Study: NCT05801718

Intervention type: DIAGNOSTIC_TEST
Intervention: Growth parameters & body mass index
Description: measuring the anthropometric measurements including: Weight, height/ length, head circumference, mid arm circumference\& skin fold thickness and measuring body mass index.
Study: NCT03981263

Intervention type: DEVICE
Group type: OTHER
Intervention: Standard prothesis
Description: This prosthesis will be compared with a standard non-adherent prosthesis (class I, silicone and polyurethane film), among the models available in the three ranges of standard prostheses (Amoena, Anita and Thuasne). The brand and model will be left to the patient's choice.

Intervention type: DEVICE
Group type: OTHER
Intervention: Standard prothesis
Description: This prosthesis will be compared with a standard non-adherent prosthesis (class I, silicone and polyurethane film), among the models available in the three ranges of standard prostheses (Amoena, Anita and Thuasne). The brand and model will be left to the patient's choice.
Study: NCT04878588

Intervention type: OTHER
Intervention: patients received high resolution impedance manometry
Description: patients received the above two examination at the same time
Study: NCT05495256

Intervention type: DEVICE
Group type: OTHER
Intervention: Respimetrix
Description: The Respimetrix device has a low resistance airflow sensor with an inhaler to measure patients inspiratory airflow and volume. This device will thereby provide quantifiable measures of lung function and bronchodilator delivery.
Study: NCT05720689

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: using relaxing music
Description: music diffusion during dental care under MEOPA
Study: NCT06398990

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: It will continue twice a week for 12 weeks. After the initial evaluation of the cases, one-on-one, face-to-face training will be provided with the patient in the first week (2 sessions) in order to ensure their compliance with the treatment and to fully understand the treatment method. Then, treatments will be carried out synchronously with the patients twice a week via the online platform (Zoom).

Intervention type: OTHER
Group type: OTHER
Intervention: Routine Medical Treatment
Description: Assessments of individuals in this group will be made face-to-face in the relevant clinic.
Study: NCT06103604

Intervention type: DIAGNOSTIC_TEST
Intervention: latest generation tympanic thermometer
Description: The patient whose core temperature is monitored during hospitalisation has his temperature at tympanic level taken once during the stay. The research nurse will record the core temperature from the monitor on the CRF and, within the next 5 minutes, take the peripheral temperature with the tympanic thermometer three times in a row, recording all three values on the CRF. Subsequently a second operator will always take the temperature 3 times within 5 minutes of the gold standard measurement. Only the first tympanic measurement will then be used to assess accuracy against the gold standard.
Study: NCT05907317

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerebral oximetry monitoring device
Description: Participants in the experimental group will be monitored with cerebral oximetry, if possible before or, as soon as possible and within six hours after initiation of invasive mechanical ventilation. Cerebral oximetry will be continued until 1) the cardio-pulmonary function has been stabilised as indicated by the need for respiratory and circulatory support and evaluated by the responsible physician, 2) extubation, 3) until 28 days after birth, or 4) until death. Randomisation will only direct the use of cerebral oximetry during the first invasive mechanical ventilation episode. Cerebral oximetry will be used to minimise cerebral hypoxia by modifying clinical care according to the SafeBoosC treatment guideline and monitoring as usual.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Treatment as usual

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Treatment as usual
Study: NCT05153759

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meal service
Description: The primary goal is to pilot the feasibility of a meal service intervention in night shift workers

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Meal service
Description: The primary goal is to pilot the feasibility of a meal service intervention in night shift workers
Study: NCT05467891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: 400 mg orally once daily Days 1-21 (28 day Cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg intramuscularly on Day 1 and 15 of Cycle 1 then Day 1 of Cycle 2+

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1 mg orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: 25 mg orally once daily
Study: NCT04928092

Intervention type: PROCEDURE
Intervention: Standard of care Ultra Low Contrast PCI
Description: PCI using low amounts of contrast media which is standard of care at VCU Medical Center
Study: NCT05750966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefrtriaxone, gentamicin, cefuroxim, ciprofloxin or other antibiotics according to local guideline (24 hours)
Description: The duration of antibiotics is 24 hours after adequate biliary drainage. The choice of antibiotics will be according to local protocol and/or national Dutch SWAB guidelines. The most common antibiotics are described above, but this can differ based on allergies, local protocol or previous cultures. Drug classes may include: aminoglycosides, carbapenems, cefalosporins, fluorquinolones, sulfonamides, penicillines.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefrtriaxone, gentamicin, cefuroxim, ciprofloxin or other antibiotics according to local guideline (4 to 7 days)
Description: The duration of antibiotics is 4 to 7 days after adequate biliary drainage. The choice of antibiotics will be according to local protocol and/or national Dutch SWAB guidelines. The most common antibiotics are described above, but this can differ based on allergies, local protocol or previous cultures. Drug classes may include: aminoglycosides, carbapenems, cefalosporins, fluorquinolones, sulfonamides, penicillines.
Study: NCT05643053

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: thomas fixation
Description: Use of the thomas tube holder for endotracheal tube fixation in patients operated in the prone position

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: elastic band
Description: Use of the elastic band for endotracheal tube fixation in patients operated in the prone position

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: normal fixation adhesive tape
Description: Use of the adhesive tape for endotracheal tube fixation in patients operated in the prone position

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reinforced adhesive tape fixation
Description: Use of the reinforced adhesive tape fixation for endotracheal tube fixation in patients operated in the prone position
Study: NCT05720689

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No relaxing music
Description: dental care under MEOPA without music